Follow-up after Barrett esophagus ablation: How do you do it, and when do you stop (if ever)?

July 16th, 2013

Follow-up after Barrett esophagus ablation: How do you do it, and when do you stop (if ever)?

We have shifted the paradigm of treating neoplastic Barrett esophagus (BE) away from a choice between intensive surveillance or surgery and towards endoscopic ablation. In the last 5 years, I have done hundreds of BE ablations using radiofrequency ablation (RFA) and endoscopic mucosal resection (EMR), and many thousands have been performed worldwide. However, on post-ablation surveillance, evidence is lacking on whether and when patients can be cut loose. Moreover, I am beginning to see patients who were believed to be cured after ablation (no signs of BE or neoplasia during years of surveillance) showing up with adenocarcinoma in the distal esophagus 4 or more years later.

Until now, I have been telling my patients that once they are BE- and dysplasia-free, I want them to undergo surveillance every 4 months for 1 year, then every 6 months for 1 year, then yearly for a couple of years, and then every other year if things remain stable.

But given the uncertainties I’ve outlined above, I am interested in discussing your practices and recommendations for surveillance after ablation for BE.

On that note, what would your approach be in the following cases?

1) If a patient with high-grade dysplasia has their BE completely ablated (no BE and no dysplasia), what surveillance period do you recommend for the following year? Year two? Beyond 2 years?

2) If a patient with low-grade dysplasia has their BE completely ablated (no BE and no dysplasia), what surveillance period do you recommend for the following year? Year two? Beyond 2 years?

3) If a patient with NO dysplasia has their BE completely ablated (no BE and no dysplasia), what surveillance period do you recommend for the following year? Year two? Beyond 2 years?

4) Do you ever tell patients that they are cured and no longer need surveillance (e.g., after 5 years, after 10 years, etc.)?

5) If a patient with dysplasia has their neoplastic BE completely ablated (no dysplasia but residual BE), what surveillance period do you recommend for the following year? Year two? Beyond 2 years?

Please join the discussion to shed some light on this issue.

Categories: Barrett esophagus, cancer surveillance, Patient care, practice environment, Uncategorized

You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Operative versus Nonoperative Management for Appendicitis July 2, 2026

This feature about treatment of appendicitis offers a case vignette accompanied by two essays, one recommending operative management and the other supporting a nonoperative approach.

Artificial Intelligence and Detection of Hirschsprung Disease July 2, 2026

This artificial intelligence–derived and validated machine-learning system appeared to predict the risk of Hirschsprung disease with the use of genetic and demographic data from participants in China.

A Major Step toward a Cure for Hepatitis B Infection June 25, 2026

The current treatment of chronic hepatitis B infection includes nucleoside or nucleotide analogue (NA) therapy and pegylated interferon. Both of these treatments are effective in suppressing hepatitis B virus (HBV) replication and in reducing the risk of cirrhosis and hepatocellular carcinoma.1 However, these treatments do not eradicate HBV,...

Prevention and Treatment of Peanut Allergy June 25, 2026

Peanuts should be introduced at 4 to 6 months of age in infants at high risk for allergy and at approximately 6 months of age in other infants. For infants with peanut allergy, early immunotherapy is safer and more effective.

Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection June 25, 2026

In two phase 3 trials, 19% of patients with chronic hepatitis B infection had a functional cure with the antisense oligonucleotide bepirovirsen, 24 weeks after stopping all HBV treatment; functional cure was not seen with placebo.

Gut Check on Gastroenterology Archive

Gut Check on Gastroenterology, an NEJM Journal Watch blog focusing on issues in clinical gastroenterology, was active from 2008 to 2014. This archive contains all posts and discussions from Gut Check’s history.

July 16th, 2013